Blog

Group 15235 1 1 (1)

The End of Sickcare: From the Inside Out: A Spotlight on Cellular Longevity at t...

There are rare moments when political urgency, scientific progress, and cultural appetite collide — creating the conditions for real transformation. This may be one of them. With skyrocketing healthcare costs…
Group 1000001206

Sen-Jam Pharmaceutical Joins Forces with The Global Passion Project for Transfor...

HUNTINGTON, N.Y., April 1, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is proud to sponsor and participate in The Global Passion Project’s upcoming Healthcare Investor Summit, taking place…
Group 1000001207 (1)

Behind the Breakthrough: Strategic Insights from Sen-Jam’s Executive Leade...

In March 2025, Sen-Jam Pharmaceutical hosted a pivotal webinar in collaboration with Destum Partners, a premier strategic advisory firm known for driving success in biotech partnerships, licensing, and M&A…
Mask Group (20)

Patent Milestone and Stability Data Strengthen Licensing Value of SJP-002C

One year ago, we filed a provisional patent application for our Upper Respiratory Infection Therapeutic – SJP-002C, covering the novel manufacturing process for our dual-acting oral therapy…
Eid Ashley Lauren St John Portrait 1 1

Sen-Jam Pharmaceutical Welcomes Immunology and Infectious Disease Expert Dr. Ash...

HUNTINGTON, N.Y., March 11, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is thrilled to announce the appointment of Dr. Ashley St. John, Ph.D., to its Scientific Advisory Board, further strengthening…
Compressed Mask Group 16

Sen-Jam Pharmaceutical Engages Destum Partners to Source Strategic Partnerships ...

HUNTINGTON, N.Y., Feb. 10, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a pioneering biotech company dedicated to innovative anti-inflammatory solutions, is pleased to announce its engagement…
Mask Group (18)

Sen-Jam Pharmaceutical Answers Surgeon General’s Alarm with a New Therapeu...

HUNTINGTON, N.Y., Jan. 27, 2025 /PRNewswire/ — A newly published paper in the Global Journal of Addiction & Rehabilitation Medicine further expands on the U.S. Surgeon General’s advisory, linking frequent alcohol…
Compressed Mask Group 21

Sen-Jam Pharmaceutical Secures Financial and Strategic Investment from 5 Horizon...

HUNTINGTON, N.Y., Jan. 22, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a leader in innovative solutions targeting inflammation and metabolic health, proudly announces a financial and strategic…
Preliminary Positive Results 1 Scaled 1

Sen-Jam Pharmaceutical Announces Preliminary Results from Phase 2 Clinical Trial...

HUNTINGTON, N.Y., Jan. 15, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is excited to announce the preliminary results from its recently completed Phase 2 clinical trial evaluating the safety and efficacy of SJP-002C…
Encouragement Original 534082 Scaled 1 1 (1)

Sen-Jam Pharmaceutical Announces Ethics Approval in Australia for SJP-001 Clinic...

HUNTINGTON, N.Y., Jan. 14, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a leader in developing innovative solutions to address inflammation at its root cause, proudly announces that its flagship asset, SJP-001…

Where the Next Spark Becomes Tomorrow’s Headline

 

Our newsroom of scientists, strategists, and culture-watchers tracks the earliest pulses in biology, policy, and public conversation—translating fresh data into actionable perspective before the rest of pharma blinks. Stay tuned, stay sharp, and stay upstream with us.

Media Inquiry